FE
Fermenta Biotech Ltd (FERMENTA)
₹446.15
Mkt cap
₹1,364 Cr
P/E ratio
29.40
P/B
3.14
Div yield
0.81%
ROE
17.30%
ROCE
20.60%
EPS (TTM)
₹15.18
Book value
₹142
52W range
249–583
Sector
Healthcare
Price history
Previous close
Incorporated in 1951, Fermenta Biotech Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products [1]
NSE FERMENTABSE 506414
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−23.43% from high₹446
₹249+79.28% from low₹583
Current
₹446.15
Prev close
₹462.30
Day
−3.49%
Price performance
1D
−4.28%
1W
−6.67%
1M
−3.46%
3M
−3.83%
6M
+44.51%
1Y
—
YTD
+40.12%
Financials
Revenue, profit & margin
P/E ratio
29.4×
FERMENTA is 12% below the sector median of 33.4×
FERMENTA29.4×
Sector median33.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 56.91 | 98.97 | 97.34 | 78.13 | 95.03 | 156.47 | 139.85 | 136.26 | 130.22 | 137.36 | 121.58 | 121.82 | 132.67 | |
| YoY Sales growth | -41.95% | +80.40% | -7.44% | -5.24% | +66.98% | +58.10% | +43.67% | +74.40% | +37.03% | -12.21% | -13.06% | -10.60% | +1.88% | |
| Expenses | 70.82 | 73.84 | 91.96 | 77.33 | 76.25 | 103.20 | 102.90 | 108.02 | 103.58 | 112.40 | 101.58 | 103.76 | 112.56 | |
| Operating Profit | -13.91 | 25.13 | 5.38 | 0.80 | 18.78 | 53.27 | 36.95 | 28.24 | 26.64 | 24.96 | 20.00 | 18.06 | 20.11 | |
| OPM % | -24.44% | 25.39% | 5.53% | 1.02% | 19.76% | 34.04% | 26.42% | 20.73% | 20.46% | 18.17% | 16.45% | 14.83% | 15.16% | |
| Other Income | -5.53 | 2.52 | 5.38 | 2.82 | 2.88 | 2.23 | 3.89 | 8.77 | 5.43 | 0.92 | 14.14 | 4.37 | 3.08 | |
| Interest | 3.69 | 5.19 | 3.39 | 3.43 | 3.69 | 4.08 | 2.99 | 3.11 | 2.58 | 3.03 | 2.82 | 2.54 | 3.73 | |
| Depreciation | 5.93 | 6.38 | 6.46 | 6.12 | 6.15 | 6.08 | 5.86 | 5.81 | 5.41 | 5.37 | 5.11 | 5.20 | 5.21 | |
| Profit before tax | -29.06 | 16.08 | 0.91 | -5.93 | 11.82 | 45.34 | 31.99 | 28.09 | 24.08 | 17.48 | 26.21 | 14.69 | 14.25 | |
| Tax % | 0.00% | 37.81% | 884.62% | 0.00% | 5.92% | 16.43% | -4.19% | 23.07% | 25.17% | 31.24% | 29.03% | 35.13% | 33.75% | |
| Net Profit | -29.07 | 9.99 | -7.14 | -5.93 | 11.12 | 37.89 | 33.32 | 21.60 | 18.03 | 12.02 | 18.60 | 9.53 | 9.44 | |
| EPS in Rs | -9.70 | 3.35 | -2.36 | -1.98 | 3.87 | 12.54 | 11.68 | 7.42 | 6.14 | 4.31 | 6.52 | 3.31 | 3.32 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202660.12%Promoter
Promoters60.12%3.96
FIIs1.05%0.92
DIIs0.00%0.04
Public36.43%3.24
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,867.50 | 36.42 | 4,48,076 | 0.86% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,080.00 | 86.07 | 2,94,139 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,691.20 | 82.19 | 1,78,438 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,220.00 | 89.52 | 1,19,949 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,192.00 | 26.24 | 1,18,902 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,377.90 | 41.11 | 1,15,092 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,394.50 | 36.28 | 1,12,660 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Fermenta Biotec. | ₹463.35 | 29.36 | 1,364 | 0.81% | 9 | −45.90% | 133 | +1.88% | 20.57% |
| Median: 160 Co. | ₹449.50 | 33.40 | 2,018 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Concall transcripts65
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Nov - Newspaper publication regarding unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2026.Announcement under Regulation 30 (LODR)-Investor Presentation 6 NovAnnouncement under Regulation 30 (LODR)-Press Release / Media Release 5 Nov - Fermenta reports H1FY27 revenue of INR 261.9 crore, EBITDA down 34% and PAT down 52% YoY.Intimation Regarding The Board'S Decision To Close The Company'S Wholly-Owned Subsidiary - Fermenta Biotech (UK) Limited. 5 Nov - Board approved closure of UK subsidiary Fermenta Biotech (UK) Limited on November 5, 2026.Board Meeting Outcome for Outcome Of Board Meeting And Unaudited Financial Results For Quarter Ended September 30, 2026. 5 Nov - Board approved Q2/H1 FY26 standalone and consolidated results; auditor gave unmodified opinion.






